FY27 Revenue Growth Target: 30-35%
Management targets approximately 30-35% revenue growth for FY27 while maintaining focus on profitability and return ratios, driven by reagent revenue growth of similar magnitude.
QLINEBIOTECH / guidance tracker
Keep management guidance in view.
Qlinebiotech · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
CDMO Revenue Target: Rs 10 Crore
Company expects CDMO business to contribute Rs 10 crore in FY27 from tech transfer and OEM partnerships, with negotiations in advanced stages with a European principal for Selectra Pro exports across 55+ countries.
Export Revenue Target: 5x Growth to Rs 6 Crore
International revenue expected to grow from Rs 1.2 crore to over Rs 6 crore in FY27 through distributor appointments in Middle East, Africa, and Mauritius with regulatory compliance completed.
Unit 4 Utilization: 25-30% by FY27
Manufacturing facility at Baddi expected to achieve 25-30% utilization in FY27 through gradual shift of clinical chemistry reagents from Delhi facility and addition of rapid molecular products.